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Unlimited self-renewal is an absolute pre-
requisite for any malignancy, and is the
ultimate arbiter of the continuous growth
and metastasis of tumors. It has been
suggested that the self-renewal proper-
ties of a tumor are exclusively contained
within a small population of “cancer stem
cells” (Reya et al., 2001). Like normal
adult somatic stem cells, these cells are
purported to have capacity for self-
renewal, and through a process of asym-
metric cell division give rise to committed
progenitors that comprise the bulk of the
tumor, but lack the ability to self-renew.
Populations of cancer stem cells, delin-
eated by differential expression of sur-
face markers or by functional properties,
have recently been demonstrated in sev-
eral cancers, including acute leukemias
(Bonnet and Dick, 1997), breast cancer
(Al-Hajj et al., 2003), and CNS tumors
(Singh et al., 2003).
The cancer stem cell model may
explain why many chemotherapeutic regi-
mens result in dramatic reductions in
tumor burden, but relapse of disease
remains one of the most significant
problems in cancer therapy. Current
chemotherapeutics may target only the
bulk, nonclonogenic tumor cells and spare
the cancer stem cells, allowing for
recrudescence of tumor following cessa-
tion of therapy. Thus, an improved under-
standing of cancer stem cells may allow
for the development of more effective ther-
apies that target this critical population.
What is the origin of the cancer stem
cell? Some data suggests that they origi-
nate from normal adult somatic stem
cells in which a transforming event has
occurred. For example, human leukemia
stem cells (LSC) are immunophenotypi-
cally similar to their tissue-specific coun-
terpart, the pluripotent hematopoietic
stem cell (HSC) in NOD-SCID mouse
transplantation models (Bonnet and
Dick, 1997). In addition, cancer-specific
chromosomal abnormalities can be
detected in stem cells, and tumor cells
and stem cells express similar levels of
telomerase. The inherent self-renewal
properties of adult stem cells, accompa-
nied by their longevity, may also predis-
pose to acquisition of the minimum
number of mutations required for malig-
nant transformation. However, it is also
possible that committed progenitor cells
could be a source of cancer stem cells if
the transforming event itself contributes
properties of self-renewal.
Chronic myelogenous leukemia
(CML) is a clonal myeloproliferative dis-
order that arises in the hematopoietic
stem cell compartment and whose
molecular signature is the BCR-ABL1
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Cancer can be viewed as a hierarchical system that is dependent on a small population of “cancer stem cells” with unlimit-
ed self-renewal potential for continued growth and propagation of tumors. The identity and nature of these cells remains
enigmatic, but an improved understanding of their biology may allow for selective therapeutic targeting. A recent report by
Jamieson et al. (2004) sheds new light on leukemia stem cells by identifying the cells with in vitro self-renewing properties
in various phases of chronic myelogenous leukemia, and linking the self-renewal properties of this population to activation
of β-catenin, a major effector of the canonical Wnt signaling pathway.
Figure 1. Comparison of stem cell ontogeny between normal hematopoiesis, chronic phase,
and blast phase CML
A: In normal hematopoiesis, the hematopoietic stem cell (HSC) is the only cell which demon-
strates activated β-catenin and self-renewal properties. In subsequent development, a combi-
nation of intrinsic and extrinsic signals ensures adequate production of mature effector cells. 
B: In chronic phase CML, the leukemic stem cell (LSC) also resides within the HSC compartment.
Similarly to its normal counterpart, it is the only cell to demonstrate activated β-catenin and
self-renewal properties, a process for which BCR-ABL appears dispensable. However, activa-
tion of numerous signaling pathways by BCR-ABL in progenitor populations directs an expan-
sion of these compartments and a subsequent expansion of terminally differentiated
neutrophils in the peripheral blood. 
C: In blast crisis (BC) CML, a second mutation results in self-renewal properties within the GMP
compartment, presumably dependent upon β-catenin activation. This second mutation may
occur within the HSC compartment, but as has been demonstrated prospectively in mouse
models, may also occur within the more committed GMP progenitor population. In contrast to
chronic phase CML, BCR-ABL appears to contribute to the self-renewal properties of this com-
partment, and in cooperation with activated β-catenin and possibly other mutations that
block differentiation and lead to the development of an acute leukemia.
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gene rearrangement. BCR-ABL1 is a
constitutively activated protein tyrosine
kinase that transforms hematopoietic
cells through the activation of multiple
signaling pathways (Deininger et al.,
2000). The stem cell nature of CML is
confirmed by demonstration of the BCR-
ABL rearrangement in multiple mature
hematopoietic lineages, and by the
potential to generate acute leukemias of
various lineages upon blast transforma-
tion (Deininger et al., 2000). CML is char-
acterized by step-wise progression,
driven by the accumulation of additional
mutations (Deininger et al., 2000). In the
initial chronic phase (CP), the myeloid
compartment is expanded, but cells
retain their capacity to differentiate and
function normally, and drug treatment is
usually effective. Progression to blast cri-
sis (BC) is characterized by a loss of dif-
ferentiation capacity and refractoriness
to therapy.
The development of imatinib mesy-
late (Gleevec) as a selective small mole-
cule inhibitor of the BCR-ABL1 kinase
represents a dramatic advance in treat-
ment of CML, and has been a harbinger
for effective therapy of solid tumors using
kinase inhibitors. Imatinib therapy of CML
results in hematological and cytogenetic
responses in CP and some BC patients.
However, these successes have been
tempered by the development of resis-
tance due to ABL kinase mutations, the
transient response to imatinib in most BC
patients, continued detection of the BCR-
ABL transcript at the molecular level in
most patients treated with imatinib, and
the finding of quiescent LSC in CML that
are resistant to imatinib (Melo et al.,
2003), indicating that additional therapies
will be necessary to cure CML.
Jamieson and colleagues have shed
new light on leukemia stem cells (LSC)
by studying patients with CML (Jamieson
et al., 2004). They provide evidence for 
a dynamic LSC compartment during
disease progression of CML, demon-
strate that self-renewal programs can
apparently be reactivated in committed
hematopoietic progenitors, and annotate
a role for interaction between BCR-ABL1
and the WNT signaling pathway in sus-
taining self-renewal. In this elegant
study, distinct populations of hematopoi-
etic progenitors were prospectively iso-
lated by multiparameter flow-sorting
(Manz et al., 2002) from patients with dif-
fering phases of CML. Surprisingly, the
size of the HSC compartment was the
same in all phases of CML, whereas
there was progressive expansion of the
myeloid progenitor compartment with
disease progression. In BC patients,
there was an increase in the size of the
granulocyte-macrophage compartment
(GMP), and subsequent analysis
demonstrated that these GMPs had
properties of self-renewal in vitro, as
assessed in serial replating assays.
Although additional work is needed to
characterize the stem cell properties of
this population, these data indicate that
the GMP population, normally lacking
any capacity for self-renewal, may
acquire certain properties of leukemic
stem cells with disease progression
(Figure 1).
Based on data from this same group
showing that WNT signaling is important
for normal HSC self-renewal (Reya et al.,
2003), the role of β-catenin, the major
effector of this pathway, in the self-
renewal of these populations was exam-
ined. Nuclear colocalization of β-catenin
detected by immunofluorescence and an
in vivo lentiviral LEF/TCF reporter assay
were used as surrogates for WNT path-
way activation. In CP CML, β-catenin
activity was restricted to the HSC frac-
tion, but in patients with BC, β-catenin
activation was detected in the GMP pop-
ulation. A direct association between β-
catenin activation and self-renewal was
supported by the ability of lentiviral trans-
fer of β-catenin to increase the in vitro
replating ability of normal GMP, and by
inhibition of serial replating of BC GMP
by transfer of the β-catenin inhibitor Axin.
In addition, in CP CML, BCR-ABL tran-
scripts were more numerous in stem
cells than progenitors, but this pattern
was reversed with progression to BC.
Taken together with the demonstration of
a decrease in β-catenin activation in the
GMP of BC patients treated with ima-
tinib, these data suggest a link between
BCR-ABL kinase activity and self-renew-
al in BC CML.
These findings have interesting impli-
cations for the origin and organization of
the LSC compartment. First, they sug-
gest that the LSC compartment either
changes, or operates on two tiers with
progression of CML (Figure 1). Second,
they demonstrate that oncogenic muta-
tions in humans may confer properties of
self-renewal to cells that lack these prop-
erties. Similar findings have been report-
ed by the Weissman/Cleary groups in
murine models of leukemia induced by
the MLL-ENL fusion (Cozzio et al., 2003),
and we have made similar observations
with the MOZ-TIF2 fusion oncogene
(unpublished observations). However, a
recent report suggests that there may be
added complexity in the interpretation of
these findings. Lentiviral marking of
human AML cells, followed by serial
transplantation into NOD-SCID mice,
identified LSCs with differing capacity for
long term self-renewal (Hope et al.,
2004). These data are consistent with
maintenance of a normal HSC hierarchy
in the LSC compartment, as suggested
by the authors. However the work of
Jamieson et al. raises the possibility that
ongoing acquisition of second mutations
that confer properties of self-renewal to
leukemic progenitors could also con-
tribute to such a hierarchy.
There are several important avenues
for further investigation, including rigor-
ous characterization of the stem cell
properties of CML GMPs and determin-
ing how broadly applicable these find-
ings are among all CML patients and in
other malignancies. These data provide
further impetus to dissect the WNT sig-
naling pathway in hematopoietic and in
solid tumors, and raise the possibility 
of therapeutic targeting of the WNT
pathway in cancer. The observation that
progenitors may acquire an ability to self-
renew is fascinating, and provides sup-
port in humans for previous observations
in murine models of disease suggesting
that certain leukemia oncogenes can
reprogram cells for self renewal poten-
tial. These in turn may be useful tools for
understanding the transcriptional pro-
grams that control self-renewal. In partic-
ular, the data suggesting an interaction
between BCR-ABL1 and WNT signaling
to confer properties of self-renewal in
GMP should be pursued. The capacity of
an “old” disease such as CML to educate
us about diverse topics in cancer biology,
including the role of chromosomal
translocations in malignancy, molecular-
ly targeted therapy of kinase-driven can-
cers, and now leukemic stem cell
ontogeny, continues to amaze.
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